

1 **Detection of Prostate Cancer Antigen 3 and Prostate Cancer Susceptibility Candidate in Non-**
2 **DRE urine Improves Diagnosis of Prostate Cancer in Chinese**

3 Lie-Fu Ye^{1, 2}, Sha He², Xiaopei Wu³, Shengying Jiang³, Ruo-Chen Zhang¹, Ze-Song Yang¹, Fa-Wen
4 Chen⁴, Dan-Ling Pan⁵, Dong Li⁶, Gang Li³

5

6 **Running title:** exoPCA3/PRAC improves diagnosis of prostate cancer in Chinese

7 ¹Department of Urology, Fujian Provincial Hospital, Fuzhou, Fujian, ²Fujian Medical University
8 Provincial Clinical College, Fuzhou, Fujian, ³Fuzhou L-BioMedx Technology Co., Ltd., Fuzhou,
9 Fujian, ⁴Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, Fujian, ⁵Department of Pathology,
10 Fujian Provincial Hospital, Fuzhou, Fujian, ⁶School of Medicine, Nankai University, Tianjin, China

11 L. Ye and S. He contributed equally to this paper.

12

13 Address Correspondence to: Gang Li, Fuzhou L-BioMedx Technology Co., Ltd., B-822, Building
14 10, Haixiyuan, Gaoxin District, Fuzhou, Fujian, China 350108

15 Phone: 086-591-62085629

16 Fax: 086-591-62085629

17 E-mail: gli9809@gmail.com

18

19 Emails for other co-authors:

20 Lie-Fu Ye yelifu@126.com

21 Sha He 1121262902@qq.com

22 Xiaopei Wu lbs_wuxp@163.com

23 Shengying Jiang 1805961889@qq.com

24 Ruo-Chen Zhang 441374690@qq.com

25 Ze-Song Yang 33320298@qq.com

26 Fa-Wen Chen chenfawen@163.com

27 Dan-Ling Pan pandanling0909@sina.com

28 Dong Li lidong@nankai.edu.cn

29

30

31

Suppl Table 1. Subjects Clinical Characteristics in Validation Cohort

Characteristic	Median (range) or %	Number (count/available)
Intended use population	100%	28
Age	65 (51-810)	28
Pre-biopsy serum PSA (ng/ml)	10.32 (4.8-17.91)	28
1-10ng/ml	46.4%	13/28
10-20ng/ml	53.6%	15/28
Suspicious DRE	10%	1/10
No prior biopsy	89.3%	25/28
Median number of cores	10 (10-12)	28
Biopsy result positive	39.3%	11/28
<u>Gleason score</u>		
GS=6 (3+3)	17.9%	5/28
GS≥7	21.4%	6/28
GS=7 (3+4)	10.7%	3/28
GS=7 (4+3)	3.6%	1/28
GS=8 (4+4)	3.6%	1/28
GS=9 (5+4)	3.6%	1/28